These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 35352535)

  • 21. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Urodynamic evaluation of the efficacy of mirabegron on storage and voiding functions in women with overactive bladder.
    Matsukawa Y; Takai S; Funahashi Y; Yamamoto T; Gotoh M
    Urology; 2015 Apr; 85(4):786-90. PubMed ID: 25709050
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability.
    Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC
    Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mirabegron for treatment of overactive bladder symptoms in patients with Parkinson's disease: A double-blind, randomized placebo-controlled trial (Parkinson's Disease Overactive bladder Mirabegron, PaDoMi Study).
    Cho SY; Jeong SJ; Lee S; Kim J; Lee SH; Choo MS; Oh SJ
    Neurourol Urodyn; 2021 Jan; 40(1):286-294. PubMed ID: 33389776
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute urodynamic effects of percutaneous posterior tibial nerve stimulation on neurogenic detrusor overactivity in patients with Parkinson's disease.
    Kabay SC; Kabay S; Yucel M; Ozden H
    Neurourol Urodyn; 2009; 28(1):62-7. PubMed ID: 18837432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Drug therapy of bladder dysfunction].
    Caremel R; Cornu JN; Kerdraon J; Castel-Lacanal E; Bastide C; Bruyere F; Guy L; Karsenty G
    Prog Urol; 2013 Nov; 23(15):1271-86. PubMed ID: 24183086
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.
    Wada N; Iuchi H; Kita M; Hashizume K; Matsumoto S; Kakizaki H
    Low Urin Tract Symptoms; 2016 Sep; 8(3):171-6. PubMed ID: 27619782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sacral Nerve Stimulation in Parkinson's Disease Patients With Overactive Bladder Symptoms.
    Greenberg DR; Sohlberg EM; Zhang CA; Santini VE; Comiter CV; Enemchukwu EA
    Urology; 2020 Oct; 144():99-105. PubMed ID: 32681915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Efficacy and safety of available therapies in the management of idiopathic overactive bladder: A systematic review of the literature].
    Moyson J; Legrand F; Vanden Bossche M; Quackels T; Roumeguère T
    Prog Urol; 2017 Mar; 27(4):203-228. PubMed ID: 28228331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Pallidal and Subthalamic Deep Brain Stimulation on Urologic Function in Parkinson's Disease.
    Mock S; Osborn DJ; Brown ET; Stuart Reynolds W; Turchan M; Pallavaram S; Rodriguez W; Dmochowski R; Tolleson CM
    Neuromodulation; 2016 Oct; 19(7):717-723. PubMed ID: 27172446
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mirabegron Add-on Therapy to Tamsulosin for the Treatment of Overactive Bladder in Men with Lower Urinary Tract Symptoms: A Randomized, Placebo-controlled Study (MATCH).
    Kakizaki H; Lee KS; Yamamoto O; Jong JJ; Katou D; Sumarsono B; Uno S; Yamaguchi O
    Eur Urol Focus; 2020 Jul; 6(4):729-737. PubMed ID: 31718957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bladder symptoms assessed with overactive bladder questionnaire in Parkinson's disease.
    Iacovelli E; Gilio F; Meco G; Fattapposta F; Vanacore N; Brusa L; Giacomelli E; Gabriele M; Rubino A; Locuratolo N; Iani C; Pichiorri F; Colosimo C; Carbone A; Palleschi G; Inghilleri M
    Mov Disord; 2010 Jul; 25(9):1203-9. PubMed ID: 20310046
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison in the efficacy of fesoterodine or mirabegron add-on therapy to silodosin for patients with benign prostatic hyperplasia complicated by overactive bladder: A randomized, prospective trial using urodynamic studies.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    Neurourol Urodyn; 2019 Mar; 38(3):941-949. PubMed ID: 30779375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis.
    Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C
    Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is benign prostatic obstruction surgery indicated for improving overactive bladder symptoms in men with lower urinary tract symptoms?
    Cornu JN; Grise P
    Curr Opin Urol; 2016 Jan; 26(1):17-21. PubMed ID: 26574877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beyond Antimuscarinics: A Review of Pharmacological and Interventional Options for Overactive Bladder Management in Men.
    De Nunzio C; Brucker B; Bschleipfer T; Cornu JN; Drake MJ; Fusco F; Gravas S; Oelke M; Peyronnet B; Tutolo M; van Koeveringe G; Madersbacher S
    Eur Urol; 2021 Apr; 79(4):492-504. PubMed ID: 33402296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ambulatory urodynamic monitoring of women with overactive bladder syndrome during single voiding cycle.
    Dokmeci F; Cetinkaya SE; Seval MM; Dai O
    Eur J Obstet Gynecol Reprod Biol; 2017 May; 212():126-131. PubMed ID: 28355584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
    Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
    Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on urological care in multiple sclerosis patients.
    Moussa M; Abou Chakra M; Papatsoris AG; Dabboucy B; Hsieh M; Dellis A; Fares Y
    Intractable Rare Dis Res; 2021 May; 10(2):62-74. PubMed ID: 33996350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.